NCT02205606View on ClinicalTrials.gov

Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

412

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

April 30, 2015

Conditions
Primary Hypercholesterolemia
Interventions
DRUG

HGP0816 5mg

P.O.

DRUG

HGP0816 10mg

P.O.

DRUG

HGP0816 20mg

P.O.

DRUG

HCP1306 5/10mg

P.O.

DRUG

HCP1306 10/10mg

P.O.

DRUG

HCP1306 20/10mg

P.O.

Trial Locations (1)

Unknown

19 institutions including Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02205606 - Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia | Biotech Hunter | Biotech Hunter